查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1438323

全球肺癌診斷市場、市場規模、預測（2024-2030）、產業趨勢、份額、成長、考慮、通貨膨脹的影響、公司分析

Lung Cancer Diagnostics Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Companies Analysis
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格

預計2030年，全球肺癌診斷市場規模將達到約308.4億美元。在現代醫學中，肺癌診斷對於早期發現和個人化治療至關重要。CT 掃描和 MRI 等先進的影像策略可以幫助識別腫瘤和轉移瘤，並有助於分期和治療計劃。生物標記測試，包括基因突變和蛋白質表現分析，可以實現個人化治療，改善治療結果，並最大限度地減少副作用。此外，液體活檢可以非侵入性地追蹤疾病進展和治療反應。技術和研究的不斷進步不斷改善肺癌診斷，有望提高存活率和生活水平。

全球肺癌診斷市場規模預計在預測期間（2024-2030年）複合年增長率為7.23%。

全球肺癌發生率的上升增加了對更好的肺癌診斷的需求。根據Lung Cancer Research Foundation的數據，吸菸是迄今為止肺癌的危險因素，佔肺癌死亡人數的 80%。同時，從不吸菸的人佔肺癌死亡人數的其餘20%。早期檢測技術，包括影像技術和生物標記測試，可以改善患者的治療結果。隨著醫療保健系統優先考慮篩檢計畫和診斷設備，全球肺癌診斷市場正在意外擴大。增加對研究、先進技術和客製化治療方法的投資將有助於加強對流行疾病的應對。

多模式診斷方法的採用正在徹底改變全球肺癌診斷市場。透過整合 CT、PET 和 MRI 等多種影像方式以及分子生物學/遺傳分析，臨床醫生可以更廣泛地了解腫瘤特徵和分期。這種方法補充了預後和治療計劃的準確性，推動了癌症診斷市場的成長。隨著早期檢測和個人化醫療的重要性被認識，對多模式診斷解決方案的需求持續增長，並正在塑造肺癌診斷的格局。因此，2023年全球肺癌診斷市場規模為189.2億美元。

北美肺癌診斷市場正在顯著擴大。這是由新技術和彈性醫療基礎設施的採用所推動的。作為創新的燈塔，我們正在製定卓越診斷的標準並刺激全球需求。此外，正在進行的研究和改進活動，特別是在癌症的早期檢測方面，有望改善全球肺癌診斷和篩檢市場，在預防這種全球流行疾病方面發揮關鍵作用。我們正在加強它。

全球肺癌診斷市場最重要的領域之一是影像學檢測。

影像檢查處於全球肺癌診斷市場的前沿。這是因為它對於腫瘤的早期發現和準確評估起著至關重要的作用。電腦斷層掃描 (CT)、正子斷層掃描 (PET) 和磁振造影 (MRI) 等技術可以幫助識別肺組織，從而幫助定位腫瘤、分期疾病並製定治療計劃。提供可視化。其非侵入性和早期發現異常的能力使其得到認可。由於不斷提高分辨率和特異性的技術進步，診斷成像已成為肺癌診斷的關鍵。這鞏固了其作為世界市場主要部門的地位。

非小細胞肺癌是全球肺癌診斷市場最重要的組成部分之一。

非小細胞肺癌（NSCLC）在全球肺癌診斷市場中佔有重要地位。這是因為其高發病率和多種治療選擇。NSCLC 極大地推動了診斷評估的需求，包括影像學、生物標記評估和組織病理學。由於其異質性，需要準確的預後和分期來選擇最高品質的治療，從而刺激診斷技術的創新。此外，針對特定 NSCLC 亞型的核心療法和免疫療法的進展進一步強調了正確診斷的重要性。由於非小細胞肺癌持續為醫療保健帶來重大負擔，其診斷階段仍然是全球肺癌診斷市場的基石。

本報告研究了全球肺癌診斷市場，並對市場成長驅動因素和挑戰以及細分市場、地區和公司進行了全面分析。

目錄

第一章簡介

第二章 研究內容及研究方法

第三章執行摘要

第四章市場動態

  • 增長動力
  • 任務

第五章 全球肺癌診斷市場

第六章市場份額-全球肺癌診斷分析

  • 按診斷測試類型
  • 按癌症類型
  • 按最終用戶
  • 按國家

第七章診斷測試類型—全球肺癌診斷市場

  • 影像學檢查
  • 活檢
  • 痰液細胞學檢查
  • 分子檢測
  • 其他

第八章癌症類型－全球肺癌診斷市場

  • 非小細胞肺癌
  • 小細胞肺癌

第九章最終用戶-全球肺癌診斷市場

  • 醫院相關研究所
  • 獨立診斷實驗室
  • 影像診斷中心
  • 癌症研究所
  • 其他

第十章國家-全球肺癌診斷市場

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 比利時
    • 荷蘭
    • 土耳其
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 泰國
    • 馬來西亞
    • 印度尼西亞
    • 澳大利亞
    • 紐西蘭
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合酋長國
    • 南非

第十一章波特五力分析-全球肺癌診斷市場

第十二章 SWOT 分析-全球肺癌診斷市場

第十三章公司分析-全球肺癌診斷市場

  • llumina
  • Abbott Laboratories
  • Thermo Fisher Scientific, Inc
  • QIAGEN N.V.
  • Roche Holding AG.
  • Sanofi S.A.
  • Agilent Technologies
  • bioMerieux

Global Lung Cancer Diagnostics Market is predicted to be valued at around US$ 30.84 Billion by 2030, according to Renub Research. In modern-day healthcare, lung cancer diagnostics are pivotal in early detection and personalized treatment. Advanced imaging strategies like CT scans and MRI permit particular identification of tumors and metastases, assisting in staging and treatment planning. Biomarker testing, inclusive of genetic mutations and protein expression analysis, allows for centered remedies tailor-made to their patients, improving results and minimizing side effects. Further, liquid biopsies offer a non-invasive tracking of disease progression and remedy responses. With non-stop improvements in technology and research, lung cancer diagnostics continue to conform, offering a want for improved survival rates and standard of life.

Global Lung Cancer Diagnostics Market is predicted to increase at a CAGR of 7.23% during the projection period (2024 to 2030)

The demand for superior lung cancer diagnostics has improved because of the rising prevalence of the disease globally. According to the Lung Cancer Research Foundation, smoking is the dominating risk element for lung cancer, accounting for 80% of lung cancer deaths. In comparison, individuals who've in no way smoked account for the remaining 20% of lung cancer deaths. Early detection techniques enhance patient outcomes, including imaging technology and biomarker testing. The global lung cancer diagnostics market is expanding unexpectedly as healthcare systems prioritize screening programs and access to diagnostic equipment. Increased investments in studies, progressive technology, and customized remedy approaches fuel an increase in coping with prevailing diseases.

Adopting multimodal diagnostic procedures is revolutionizing the global lung cancer diagnostics market. Clinicians gain broad insights into tumor characteristics and staging by integrating diverse imaging modalities like CT, PET, and MRI alongside molecular and genetic analyses. This approach complements accuracy in prognosis and treatment planning, driving the growth of the cancer diagnostics market. With increasing recognition of the importance of early detection and personalized medicinal drugs, the demand for multimodal diagnostic solutions continues to push upward, shaping the landscape of lung cancer diagnostics worldwide. Hence, the global lung cancer diagnostics market was US$ 18.92 Billion in 2023.

The North America lung cancer diagnostic market has witnessed considerable expansion. This is fueled by adopting contemporary technology and a resilient healthcare infrastructure. As a beacon of innovation, it sets standards for diagnostic excellence, spurring worldwide demand. Moreover, ongoing studies and improvement endeavors, specifically in early cancer detection, promise to elevate the lung cancer diagnostic and screening market worldwide, reinforcing its pivotal role in preventing this pervasive sickness worldwide.

One of the most critical areas of the lung cancer diagnostics market worldwide is imaging tests

By diagnosis test type, the global lung cancer diagnostics market is fragmented into Imaging Tests, Biopsy, Sputum Cytology, Molecular Tests, and Others. Imaging tests stand among the forefront sections of the global lung cancer diagnostics market. This is due to their pivotal function in early detection and correct assessment of tumors. Technologies like computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI) offer specified visualization of lung tissue, helping in tumor localization, staging, and remedy planning. Their non-invasive nature and capability to stumble on abnormalities at early phases contribute to their recognition. Imaging assessments are vital in lung cancer diagnosis, thanks to non-stop technological improvements that enhance resolution and specificity. This has solidified their function as a leading section in the worldwide market.

Non-Small Cell Lung Cancer is among the most significant elements in the global lung cancer diagnostics market

The global lung cancer diagnostics market is split by cancer type into non-small and small-cell lung cancer. Non-Small Cell Lung Cancer (NSCLC) holds one of the prominent positions in the global lung cancer diagnostics market. This is due to its high incidence and numerous treatment alternatives. NSCLC drives considerable demand for diagnostic assessments, which include imaging, biomarker evaluation, and histopathology. Its heterogeneous nature necessitates a precise prognosis and staging for top-quality remedy choice, spurring innovation in diagnostic technology. Moreover, advancements in centered treatments and immunotherapies tailor-made to particular NSCLC subtypes further underscore the importance of correct diagnosis. As NSCLC continues to pose a substantial healthcare burden, its diagnostic stage remains a cornerstone of the global lung cancer diagnostics market.

Hospital Associated Labs are integral to the global lung cancer diagnostics market

By end-user, the global lung cancer diagnostics market is categorized into Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others. Hospital Associated Labs is one of the most used in the global lung cancer diagnostics market. This is due to their accessibility and comprehensive services. Situated in healthcare centers, these labs offer short turnaround times for diagnostic tests, including imaging, biopsies, and molecular analyses. Their close collaboration with clinicians facilitates seamless patient care, making them a preferred choice for accurate and well-timed lung cancer analysis and treatment planning.

United States may continue to maintain its lead in the global market for lung cancer diagnostics

By country, the global lung cancer diagnostics market is divided into North America (United States, Canada), Europe (France, Germany, Italy, Spain, United Kingdom, Belgium, the Netherlands, and Turkey), Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, and New Zealand), Latin America (Brazil, Mexico, and Argentina), Middle East & Africa (South Africa, Saudi Arabia, and the UAE). The United States might stay dominant in the global lung cancer diagnostics market. This is pushed by the increasing occurrence of neurological disorders, contributing to improving the area's lung cancer diagnostics market.

For example, in line with a record by the American Society of Clinical Oncology (ASCO) in 2023, 81% of all lung cancer diagnoses in the United States were non-small cell lung cancers (NSCLC). Moreover, the United States has a sturdy healthcare system with advanced diagnostic tools, most lung cancer cases, and a focus on early detection and customized medication. It invests closely in R&D, propelling innovation and setting global lung cancer diagnosis standards.

Key Players

The global lung cancer diagnostics market comprises of leading companies like llumina, Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V., Roche Holding AG., Sanofi S.A., Agilent Technologies, and bioMerieux.

In October 2023 - DELFI Diagnostics recently announced the launch of FirstLook Lung, a blood-based test that provides a new and more accessible way to detect lung cancer. This test offers a convenient, accurate, and personalized result by determining the likelihood of detecting lung cancer through low-dose CT (LDCT) with a negative predictive value (NPV) of 99.7 percent.

Diagnosis Test Type - Market breakup in 5 viewpoints:

1. Imaging Test

2. Biopsy

3. Sputum Cytology

4. Molecular Test

5. Others

Cancer Type - Market breakup in 2 viewpoints:

1. Non- Small Cell Lung Cancer

2. Small Cell Lung Cancer

End-User - Market breakup in 5 viewpoints:

1. Hospital Associated Labs

2. Independent Diagnostic Laboratories

3. Diagnostic Imaging Centers

4. Cancer Research Institutes

5. Others

Country - Market breakup in 25 Countries:

1. North America

  • 1.1 United States
  • 1.2 Canada

2. Europe

  • 2.1 France
  • 2.2 Germany
  • 2.3 Italy
  • 2.4 Spain
  • 2.5 United Kingdom
  • 2.6 Belgium
  • 2.7 Netherlands
  • 2.8 Turkey

3. Asia Pacific

  • 3.1 China
  • 3.2 Japan
  • 3.3 India
  • 3.4 South Korea
  • 3.5 Thailand
  • 3.6 Malaysia
  • 3.7 Indonesia
  • 3.8 Australia
  • 3.9 New Zealand

4. Latin America

  • 4.1 Brazil
  • 4.2 Mexico
  • 4.3 Argentina

5. Middle East & Africa

  • 5.1 Saudi Arabia
  • 5.2 UAE
  • 5.3 South Africa

All the Key players have been covered from 3 Viewpoints:

  • Overview
  • Recent Development
  • Revenue Analysis

Company Analysis:

1. llumina

2. Abbott Laboratories

3. Thermo Fisher Scientific, Inc.

4. QIAGEN N.V.

5. Roche Holding AG.

6. Sanofi S.A.

7. Agilent Technologies

8. bioMerieux.

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Global Lung Cancer Diagnostics Market

6. Market Share - Global Lung Cancer Diagnostics Analysis

  • 6.1 By Diagnosis Test Type
  • 6.2 By Cancer Type
  • 6.3 By EndUsers
  • 6.4 By Country

7. Diagnosis Test Type - Global Lung Cancer Diagnostics Market

  • 7.1 Imaging Test
  • 7.2 Biopsy
  • 7.3 Sputum Cytology
  • 7.4 Molecular Test
  • 7.5 Others

8. Cancer Type - Global Lung Cancer Diagnostics Market

  • 8.1 Non- Small Cell Lung Cancer
  • 8.2 Small Cell Lung Cancer

9. End-User - Global Lung Cancer Diagnostics Market

  • 9.1 Hospital Associated Labs
  • 9.2 Independent Diagnostic Laboratories
  • 9.3 Diagnostic Imaging Centers
  • 9.4 Cancer Research Institutes
  • 9.5 Others

10. Country - Global Lung Cancer Diagnostics Market

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
  • 10.2 Europe
    • 10.2.1 France
    • 10.2.2 Germany
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Belgium
    • 10.2.7 Netherlands
    • 10.2.8 Turkey
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Thailand
    • 10.3.6 Malaysia
    • 10.3.7 Indonesia
    • 10.3.8 Australia
    • 10.3.9 New Zealand
  • 10.4 Latin America
    • 10.4.1 Brazil
    • 10.4.2 Mexico
    • 10.4.3 Argentina
  • 10.5 Middle East & Africa
    • 10.5.1 Saudi Arabia
    • 10.5.2 UAE
    • 10.5.3 South Africa

11. Porter's Five Analysis - Global Lung Cancer Diagnostics Market

  • 11.1 Bargaining Power of Buyers
  • 11.2 Bargaining Power of Suppliers
  • 11.3 Degree of Rivalry
  • 11.4 Threat of New Entrants
  • 11.5 Threat of Substitutes

12. SWOT Analysis - Global Lung Cancer Diagnostics Market

  • 12.1 Strength
  • 12.2 Weakness
  • 12.3 Opportunity
  • 12.4 Threat

13. Company Analysis - Global Lung Cancer Diagnostics Market

  • 13.1 llumina
    • 13.1.1 Overviews
    • 13.1.2 Recent Development
    • 13.1.3 Revenues
  • 13.2 Abbott Laboratories
    • 13.2.1 Overviews
    • 13.2.2 Recent Development
    • 13.2.3 Revenues
  • 13.3 Thermo Fisher Scientific, Inc
    • 13.3.1 Overviews
    • 13.3.2 Recent Development
    • 13.3.3 Revenues
  • 13.4 QIAGEN N.V.
    • 13.4.1 Overviews
    • 13.4.2 Recent Development
    • 13.4.3 Revenues
  • 13.5 Roche Holding AG.
    • 13.5.1 Overviews
    • 13.5.2 Recent Development
    • 13.5.3 Revenues
  • 13.6 Sanofi S.A.
    • 13.6.1 Overview
    • 13.6.2 Recent Development
    • 13.6.3 Financial Insights
  • 13.7 Agilent Technologies
    • 13.7.1 Overview
    • 13.7.2 Recent Development
    • 13.7.3 Financial Insights
  • 13.8 bioMerieux
    • 13.8.1 Overview
    • 13.8.2 Recent Development
    • 13.8.3 Financial Insights

List of Figures

  • Figure-01: Global - Lung Cancer Diagnostics Market (Billion US$), 2019 - 2023
  • Figure-02: Global - Forecast for Lung Cancer Diagnostics Market (Billion US$), 2024 - 2030
  • Figure-03: Diagnosis Test Type - Imaging Test Market (Million US$), 2019 - 2023
  • Figure-04: Diagnosis Test Type - Forecast for Imaging Test Market (Million US$), 2024 - 2030
  • Figure-05: Diagnosis Test Type - Biopsy Market (Million US$), 2019 - 2023
  • Figure-06: Diagnosis Test Type - Forecast for Biopsy Market (Million US$), 2024 - 2030
  • Figure-07: Diagnosis Test Type - Sputum Cytology Market (Million US$), 2019 - 2023
  • Figure-08: Diagnosis Test Type - Forecast for Sputum Cytology Market (Million US$), 2024 - 2030
  • Figure-09: Diagnosis Test Type - Molecular Test Market (Million US$), 2019 - 2023
  • Figure-10: Diagnosis Test Type - Forecast for Molecular Test Market (Million US$), 2024 - 2030
  • Figure-11: Diagnosis Test Type - Others Market (Million US$), 2019 - 2023
  • Figure-12: Diagnosis Test Type - Forecast for Others Market (Million US$), 2024 - 2030
  • Figure-13: Cancer Type - Non- Small Cell Lung Cancer Market (Million US$), 2019 - 2023
  • Figure-14: Cancer Type - Forecast for Non- Small Cell Lung Cancer Market (Million US$), 2024 - 2030
  • Figure-15: Cancer Type - Small Cell Lung Cancer Market (Million US$), 2019 - 2023
  • Figure-16: Cancer Type - Forecast for Small Cell Lung Cancer Market (Million US$), 2024 - 2030
  • Figure-17: End-User - Hospital Associated Labs Market (Million US$), 2019 - 2023
  • Figure-18: End-User - Forecast for Hospital Associated Labs Market (Million US$), 2024 - 2030
  • Figure-19: End-User - Independent Diagnostic Laboratories Market (Million US$), 2019 - 2023
  • Figure-20: End-User - Forecast for Independent Diagnostic Laboratories Market (Million US$), 2024 - 2030
  • Figure-21: End-User - Diagnostic Imaging Centers Market (Million US$), 2019 - 2023
  • Figure-22: End-User - Forecast for Diagnostic Imaging Centers Market (Million US$), 2024 - 2030
  • Figure-23: End-User - Cancer Research Institutes Market (Million US$), 2019 - 2023
  • Figure-24: End-User - Forecast for Cancer Research Institutes Market (Million US$), 2024 - 2030
  • Figure-25: End-User - Others Market (Million US$), 2019 - 2023
  • Figure-26: End-User - Forecast for Others Market (Million US$), 2024 - 2030
  • Figure-27: United States - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-28: United States - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-29: Canada - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-30: Canada - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-31: France - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-32: France - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-33: Germany - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-34: Germany - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-35: Italy - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-36: Italy - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-37: Spain - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-38: Spain - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-39: United Kingdom - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-40: United Kingdom - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-41: Belgium - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-42: Belgium - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-43: Netherlands - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-44: Netherlands - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-45: Turkey - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-46: Turkey - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-47: China - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-48: China - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-49: Japan - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-50: Japan - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-51: India - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-52: India - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-53: South Korea - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-54: South Korea - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-55: Thailand - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-56: Thailand - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-57: Malaysia - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-58: Malaysia - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-59: Indonesia - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-60: Indonesia - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-61: Australia - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-62: Australia - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-63: New Zealand - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-64: New Zealand - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-65: Brazil - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-66: Brazil - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-67: Mexico - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-68: Mexico - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-69: Argentina - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-70: Argentina - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-71: Saudi Arabia - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-72: Saudi Arabia - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-73: UAE - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-74: UAE - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-75: South Africa - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-76: South Africa - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-77: llumina - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
  • Figure-78: llumina - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
  • Figure-79: Abbott Laboratories - Global Revenue (Million US$), 2019 - 2023
  • Figure-80: Abbott Laboratories - Forecast for Global Revenue (Million US$), 2024 - 2030
  • Figure-81: Thermo Fisher Scientific, Inc - Global Revenue (Million US$), 2019 - 2023
  • Figure-82: Thermo Fisher Scientific, Inc - Forecast for Global Revenue (Million US$), 2024 - 2030
  • Figure-83: QIAGEN N.V. - Global Revenue (Million US$), 2019 - 2023
  • Figure-84: QIAGEN N.V. - Forecast for Global Revenue (Million US$), 2024 - 2030
  • Figure-85: Roche Holding AG. - Global Revenue (Million US$), 2019 - 2023
  • Figure-86: Roche Holding AG. - Forecast for Global Revenue (Million US$), 2024 - 2030
  • Figure-87: Sanofi S.A. - Global Revenue (Million US$), 2019 - 2023
  • Figure-88: Sanofi S.A. - Forecast for Global Revenue (Million US$), 2024 - 2030
  • Figure-89: Agilent Technologies - Global Revenue (Million US$), 2019 - 2023
  • Figure-90: Agilent Technologies - Forecast for Global Revenue (Million US$), 2024 - 2030
  • Figure-91: bioMerieux - Global Revenue (Million US$), 2019 - 2023
  • Figure-92: bioMerieux - Forecast for Global Revenue (Million US$), 2024 - 2030

List of Tables

  • Table-01: Global - Lung Cancer Diagnostics Market Share by Diagnosis Test Type (Percent), 2019 - 2023
  • Table-02: Global - Forecast for Lung Cancer Diagnostics Market Share by Diagnosis Test Type (Percent), 2024 - 2030
  • Table-03: Global -Lung Cancer Diagnostics Market Share by Cancer Type (Percent), 2019 - 2023
  • Table-04: Global - Forecast for Lung Cancer Diagnostics Market Share by Cancer Type (Percent), 2024 - 2030
  • Table-05: Global - Lung Cancer Diagnostics Market Share by End-User (Percent), 2019 - 2023
  • Table-06: Global - Forecast for Lung Cancer Diagnostics Market Share by End-User (Percent), 2024 - 2030
  • Table-07: Global - Lung Cancer Diagnostics Market Share by Region (Percent), 2019 - 2023
  • Table-08: Global - Forecast for Lung Cancer Diagnostics Market Share by Region (Percent), 2024 - 2030